Your browser doesn't support javascript.
loading
Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies.
Duan, Hongying; Chen, Xuejun; Boyington, Jeffrey C; Cheng, Cheng; Zhang, Yi; Jafari, Alexander J; Stephens, Tyler; Tsybovsky, Yaroslav; Kalyuzhniy, Oleksandr; Zhao, Peng; Menis, Sergey; Nason, Martha C; Normandin, Erica; Mukhamedova, Maryam; DeKosky, Brandon J; Wells, Lance; Schief, William R; Tian, Ming; Alt, Frederick W; Kwong, Peter D; Mascola, John R.
Afiliação
  • Duan H; Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
  • Chen X; Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
  • Boyington JC; Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
  • Cheng C; Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
  • Zhang Y; Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
  • Jafari AJ; Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
  • Stephens T; Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
  • Tsybovsky Y; Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
  • Kalyuzhniy O; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Zhao P; Complex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USA.
  • Menis S; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Nason MC; Biostatistics Research Branch, Division of Clinical Research, NIAID, NIH, Bethesda, MD 20852, USA.
  • Normandin E; Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
  • Mukhamedova M; Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
  • DeKosky BJ; Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA; Department of Chemical & Petroleum Engineering, The University of Kansas, Lawrence, KS 66045, USA; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045, USA.
  • Wells L; Complex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USA.
  • Schief WR; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Tian M; Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Alt FW; Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Kwong PD; Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
  • Mascola JR; Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA. Electronic address: jmascola@nih.gov.
Immunity ; 49(2): 301-311.e5, 2018 08 21.
Article em En | MEDLINE | ID: mdl-30076101
ABSTRACT
An important class of HIV-1 broadly neutralizing antibodies, termed the VRC01 class, targets the conserved CD4-binding site (CD4bs) of the envelope glycoprotein (Env). An engineered Env outer domain (OD) eOD-GT8 60-mer nanoparticle has been developed as a priming immunogen for eliciting VRC01-class precursors and is planned for clinical trials. However, a substantial portion of eOD-GT8-elicited antibodies target non-CD4bs epitopes, potentially limiting its efficacy. We introduced N-linked glycans into non-CD4bs surfaces of eOD-GT8 to mask irrelevant epitopes and evaluated these mutants in a mouse model that expressed diverse immunoglobulin heavy chains containing human IGHV1-2∗02, the germline VRC01 VH segment. Compared to the parental eOD-GT8, a mutant with five added glycans stimulated significantly higher proportions of CD4bs-specific serum responses and CD4bs-specific immunoglobulin G+ B cells including VRC01-class precursors. These results demonstrate that glycan masking can limit elicitation of off-target antibodies and focus immune responses to the CD4bs, a major target of HIV-1 vaccine design.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sítios de Ligação de Anticorpos / Anticorpos Anti-HIV / Antígenos CD4 / HIV-1 / Anticorpos Neutralizantes Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Immunity Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sítios de Ligação de Anticorpos / Anticorpos Anti-HIV / Antígenos CD4 / HIV-1 / Anticorpos Neutralizantes Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Immunity Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos